Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Alliance Foundation Trials (AFT) and Natera have launched the AFT-70 NAVIGATE trial, a global Phase III study in breast cancer. This trial will evaluate a novel MRD-guided treatment strategy for ER-positive/HER2-negative early breast cancer patients, using Natera's Signatera Genome test and Genentech’s investigational oral SERD, giredestrant. The aim is to optimize CDK4/6 inhibitor therapy, potentially sparing patients unnecessary exposure and associated toxicities while maintaining excellent outcomes.
Price to sales forward of Natera, Inc. – HAN:45E
This article provides financial information for Natera, Inc. (HAN:45E) on the Hannover Stock Exchange, specifically focusing on its price-to-sales forward metric. The content indicates that the market is closed, with no trades, and details are provided by ICE Data Services and FactSet.
Natera (NTRA) CEO and President Steven Chapman Sells 1,273 Shares
Natera's CEO and President, Steven Chapman, sold 1,273 shares of NTRA on October 1, 2026, valued at approximately $526,000, adding to a consistent pattern of selling over the past year. This insider selling, along with a total of 126 insider sells versus zero buys at the company, occurs while the stock is classified as "Significantly Overvalued" by GuruFocus, trading at 1.87 times its GF Value. Despite the insider sales and high valuation, 13 gurus hold NTRA shares, with more adding than trimming, suggesting a divergence in sentiment between insiders and institutional investors.
Natera (NTRA) clinical diagnostics president sells 3,000 shares under a trading plan.
Solomon Moshkevich, Natera's President of Clinical Diagnostics, sold 3,000 common shares of NTRA on October 1, 2026, through three separate transactions. These sales were executed under a Rule 10b5-1 trading plan that was adopted on November 26, 2024. The shares were sold at weighted average prices ranging from $411.6200 to $415.0691, totaling approximately $1.24 million, leaving Moshkevich with 106,914 shares of common stock.
Natera president Solomon Moshkevich sells $1.24m in shares
Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold over $1.24 million worth of company shares on October 1, 2026, through a pre-arranged trading plan. This sale occurred while Natera's stock was trading near its 52-week high, and InvestingPro analysis suggests the stock is currently overvalued. Despite the insider sale, Natera recently reported strong Q2 revenues, raised its full-year guidance, and received positive analyst ratings for its leadership in minimal residual disease (MRD) testing.
Natera CEO Steven Chapman sells $526k in common stock
Natera CEO Steven Chapman sold 1,273 shares of Natera (NASDAQ: NTRA) common stock for approximately $526,143 on October 1, 2026, under a pre-arranged trading plan. This transaction occurred as the stock trades near its 52-week high and is considered overvalued by InvestingPro analysis, despite recent positive news like exceeding revenue expectations and increased price targets from RBC Capital and Rothschild Redburn due to its strong position in MRD testing.
Natera Price Target Raised to $475.00/Share From $360.00 by Guggenheim
Guggenheim has increased its price target for Natera (NTRA) shares to $475.00, up from the previous target of $360.00. This adjustment reflects a significant uplift in the analyst's valuation of the company's stock.
Morgan Stanley Smith Barney is broker for a proposed 1,273-share sale at Natera (NTRA).
Natera, Inc. (NTRA) Officer and Director Steven Leonard Chapman has proposed to sell 1,273 common shares, with an aggregate market value of $526,143.63. Morgan Stanley Smith Barney LLC is identified as the broker for this transaction, which has an approximate sale date of October 1, 2026. This proposed sale is detailed in an SEC Form 144 filing, outlining the terms and conditions under Rule 144.
After five sales in three months, a Natera (NTRA) officer proposes another stock sale.
Solomon Moshkevich, an officer at Natera, Inc. (NTRA), has proposed selling 3,000 common shares valued at approximately $1.24 million through Morgan Stanley Smith Barney, with an approximate sale date of October 1, 2026. This proposed sale follows five earlier common stock sales by Moshkevich between July 27 and September 2, 2026. The notice also indicates 144,144,170 common shares outstanding for Natera.
Natera CEO Steve Chapman: Treatment on Molecular Recurrence Will Reshape Oncology in 5 Years
Natera CEO Steve Chapman believes that "treatment on molecular recurrence" will fundamentally reshape oncology within five years, driven by the company's significant R&D investment in its Signatera test. This approach involves administering cancer drugs upon molecular recurrence detected by blood tests, rather than waiting for tumors to appear on scans. The strategy is supported by trial data and aims to expand rapidly, with key watchpoints for investors including Medicare coverage decisions, major trial readouts, and a planned early cancer detection study launch.
Natera stock hits all-time high at 422.19 USD
Natera Inc. (NTRA) stock reached an all-time high of $422.19, reflecting a 157.35% increase over the past year and a 107% surge in the last six months. This milestone follows the company's strong second-quarter revenue, exceeding expectations, and positive analyst coverage due to its leadership in minimal residual disease (MRD) testing. Despite its current valuation appearing overvalued according to InvestingPro, analysts anticipate continued growth, particularly in the substantial MRD testing market.
$1000 Invested In Natera 5 Years Ago Would Be Worth This Much Today
Natera (NASDAQ: NTRA) has significantly outperformed the market over the last five years, with an annualized return of 29.65%. An investment of $1000 in Natera five years ago would now be worth $3,694.99, demonstrating the power of compounded returns. The company currently has a market capitalization of $59.35 billion.
Form 4 Natera Inc For: 25 September By Investing.com
This article reports on a Form 4 filing for Natera Inc. on September 25, as published by Investing.com. It indicates that the document is related to insider trading activities of the company. The article provides the title and source, with the main content being the notice of the filing itself.
Natera director Sheena’s trusts dispose of $7.0m in NTRA stock
Jonathan Sheena, a director and co-founder of Natera, Inc., had trusts associated with him sell Natera common stock worth over $7 million on September 23, 2026. The sales were conducted via a Rule 10b5-1 trading plan, with shares sold at prices between $385.1025 and $390.525. Despite the sales, Natera's stock has surged 153% over the past year and is trading near its 52-week high, although InvestingPro analysis suggests it may be overvalued.
Under a preset plan, two trusts sold 18,064 Natera (NTRA) shares in 12 transactions.
Natera director and co-founder Sheena Jonathan, through Caraluna 1 Trust and Caraluna 2 Trust, reported the sale of 18,064 common shares of Natera (NTRA) on September 23, 2026. These sales, totaling approximately $7.01 million, were executed across 12 transactions under a Rule 10b5-1 trading plan adopted on June 11, 2026. Jonathan disclaimed beneficial ownership of these shares, which were held for the trusts' beneficiaries.
Natera options flow shows 12.6:1 put/call ratio near 52-week high
Natera Inc. (NTRA) is showing a highly bearish options flow with a put/call ratio of 12.6:1, despite the stock trading near its 52-week high of $415.75. This significant options activity, particularly in out-of-the-money put contracts, suggests either hedging by long-term holders or a speculative directional bet against the stock, which has seen substantial gains recently. Insider selling activity also adds a structural red flag to the situation.
RBC Raises Price Target on Natera to $460 From $350, Keeps Outperform Rating
RBC Capital has increased its price target for Natera (NTRA) to $460, up from $350, while maintaining an "Outperform" rating on the stock. This adjustment comes as Natera continues to present at various healthcare conferences and reports on significant developments, such as the largest MRD dataset in lung cancer. The company specializes in cell-free DNA and genetic testing, focusing on oncology, women's health, and organ health.
RBC Raises Price Target on Natera to $460 From $350, Keeps Outperform Rating
RBC Capital Markets has raised its price target for Natera (NTRA) from $350 to $460, while maintaining an "Outperform" rating on the stock. This update comes as Natera continues to have an average analyst rating of "overweight" with a mean price target of $352.80, indicating a positive outlook from analysts despite the premium content requirement for full article access.
$8.2M stock sale planned at Natera (NASDAQ: NTRA)
Natera director Jonathan Sheena plans to sell 21,064 common shares, valued at approximately $8.16 million, through Charles Schwab & Co., Inc. The proposed sale is slated for September 23, 2026. This notice also details nine previous common-share sales by Sheena within the last three months, ranging from 109 to 9,150 shares individually.
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx
Natera's Signatera test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) as a companion diagnostic (CDx) for muscle-invasive bladder cancer (MIBC). This marks Natera's second PMDA authorization for Signatera in three months, with commercial launch in Japan expected in the first half of 2027. The approval is based on data from the IMvigor011 clinical trial and is anticipated to expand Signatera's adoption, enhancing Natera's presence in the precision oncology market, and driving its stock performance.
A Look at Natera Inc (NTRA) After 5.5% Gain -- GF Value $219.69 vs Price $390.90
Natera Inc (NTRA) saw its shares rise 5.5% to $390.90, but GuruFocus's GF Value suggests the stock is 77.9% overvalued at $219.69. The company has strong growth potential (Growth Rank 10/10) but struggles with profitability (Profitability Rank 3/10) and has seen significant insider selling without buying. Investors are advised to exercise caution due to its overvaluation and lack of profitability.
Behavioral Patterns of NTRA and Institutional Flows
This article analyzes Natera Inc. (NASDAQ: NTRA) focusing on its behavioral patterns and institutional flows. It highlights strong sentiment across all time horizons, indicating an overweight bias, and notes a current breakout with potential for higher levels due to the absence of resistance. The analysis provides specific trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal strengths.
Natera gains as fresh Signatera lung cancer data and upbeat analyst sentiment support shares
Natera (NTRA) shares rose by 4.3% due to investor excitement over new Signatera data for lung cancer, which demonstrated strong prognostic value. The stock also benefited from positive analyst sentiment and recent price target increases. The company's strong Q2 2026 financial performance, including significant revenue and oncology test-volume growth, further supported investor confidence.
Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Natera's Signatera test has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) as a companion diagnostic in muscle-invasive bladder cancer (MIBC). This approval supports using Signatera to guide adjuvant atezolizumab treatment decisions for MIBC patients, with a commercial launch expected in the first half of 2027. This marks Signatera's second PMDA authorization in Japan, following its approval in colorectal cancer, and underscores the growing partnership between Natera and the Japanese oncology community.
Natera Inc stock reaches all-time high at 373.58 USD
Natera Inc. (NTRA) stock has reached an all-time high of $373.58, surpassing its 52-week high and demonstrating significant growth over the past year. This surge is attributed to strong performance, robust revenue growth, impressive Q2 earnings, and positive analyst coverage, despite InvestingPro indicating the stock may be overvalued.
A cancer test receives its second Japan approval in three months to guide bladder-cancer treatment.
Natera, Inc. (NASDAQ: NTRA) announced that its Signatera test has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) as a companion diagnostic (CDx) for muscle-invasive bladder cancer (MIBC). This approval allows Signatera to guide adjuvant atezolizumab treatment decisions for MIBC patients, marking its second PMDA authorization in Japan. Commercial launch is anticipated in the first half of 2027, following atezolizumab's approval in MIBC and pending reimbursement and pricing.
Enterprise value to EBITDA ratio of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA.CI
This article displays the enterprise value to EBITDA ratio for Natera Inc Cert Deposito Arg Repr 0.019607 Sh (BCBA:NTRA.CI) on the Buenos Aires Stock Exchange. It indicates that the market is currently closed with no trades recorded for this particular security. The content primarily serves as a financial data point within a larger financial platform context.
Natera (NTRA) Stock Fair Value Rises After Signatera And Guidance Drive Analyst Revisions
Natera's stock fair value has increased to US$344.33 from US$282.14, a 22% change, primarily due to strong execution in molecular residual disease testing with Signatera and contributions from prenatal and broader oncology testing. Analysts like UBS, Citi, and Morgan Stanley have raised price targets, highlighting Natera's leadership in the molecular residual disease market and positive regulatory developments. While some analysts like Baird and Barclays trimmed price targets, they maintained positive ratings, citing higher stock multiples and expectations as potential near-term challenges.
Natera at Morgan Stanley conference: mrD growth, new bets By Investing.com
Natera showcased its ongoing growth story at the Morgan Stanley 24th Annual Global Healthcare Conference, emphasizing rapidly increasing oncology demand, strengthened women's health momentum, and upcoming product launches. The company highlighted its commitment to heavy investment in research and development, prioritizing long-term growth over immediate profits, with a particular focus on the underappreciated MRD market and early cancer detection. Natera also discussed key advancements like FDA approval for muscle-invasive bladder cancer, new guideline inclusions, and strategic applications of AI to boost efficiency and enhance product offerings.
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares
Matthew Rabinowitz, Executive Chairman of Natera, Inc., sold 50,000 shares of company stock for $16.4 million on September 11, 2026, executed through a pre-arranged trading plan. This sale occurred while Natera's stock traded near its 52-week high after a 95% return over the past year. The company recently reported strong Q2 revenues, raised full-year guidance, and received a "Buy" rating from Rothschild Redburn, indicating a positive outlook.
Jim Cramer Calls Natera (NTRA) “a Promising Story”
Jim Cramer highlighted Natera (NTRA) as "an intriguing story" due to its expansion in oncology, women's health, and organ transplantation, acknowledging its strong revenue growth and market potential, particularly with its Signatera cancer test. However, he cautioned investors about the stock's high valuation after a significant rally and its current unprofitability, advising to wait for a pullback before buying. Cramer also noted increasing hedge fund ownership but emphasized the company's valuation risks and competition.
Rothschild Redburn initiates Natera stock with buy on MRD leadership By Investing.com
Rothschild Redburn has initiated coverage on Natera Inc. (NASDAQ: NTRA) with a Buy rating and a price target of $385.00, citing the company's leadership in minimal residual disease (MRD) testing. Natera's stock, which has surged 96% over the past year, is expected to see a 22% revenue compound annual growth rate from 2026 through 2029. Despite appearing overvalued by some metrics, the firm anticipates gradual profitability improvements and continued revenue growth, supported by recent strong financial performance.
Natera president Solomon Moshkevich sells over $5.9m in shares
Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., recently sold approximately $5.92 million worth of company stock over two days, September 1 and September 2, 2026. These sales, including transactions under a Rule 10b5-1 trading plan and for tax obligations, occurred as Natera's stock traded near its 52-week high, having delivered a significant 97% return over the past year. Following the sales, Mr. Moshkevich still holds 110,859 shares, and the company has shown strong performance with a $47.2 billion valuation and 38% revenue growth.
Natera settles class action over prenatal tests for $8.25M
A federal judge has approved an $8.25 million settlement in a class action lawsuit against genetic testing company Natera. The lawsuit alleged that Natera marketed its prenatal tests as highly accurate despite knowing they could produce false positives, potentially influencing decisions about pregnancies. As part of the settlement, Natera will add disclaimers to its website clarifying that its prenatal tests are for screening purposes only, not diagnosis.
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
Natera, Inc., a leader in cell-free DNA testing, has announced a national partnership with Susan G. Komen to accelerate breast cancer awareness, education, and research. Natera will support Komen's "Race for the Cure" and "MORE THAN PINK Walk" events as a 2026 Premier National Series Sponsor, aiming to advance personalized care and improve patient outcomes. This collaboration emphasizes the importance of early detection and personalized medicine in the fight against breast cancer.
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
Natera and Angiex have partnered to use Natera's Signatera test for monitoring treatment response in Angiex's Phase I clinical trial of AGX101, an investigational Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC). This collaboration aims to evaluate whether longitudinal circulating tumor DNA (ctDNA) measurements can complement imaging and enhance the understanding of AGX101's efficacy in patients with advanced solid tumors. AGX101 is designed to target tumor cells and tumor vasculature, and the Signatera test is expected to provide early biologic response assessment.
Court Win Over Natera Patents Could Be A Game Changer For NeoGenomics’ (NEO) RaDaR ST
NeoGenomics (NEO) recently secured a favorable North Carolina court ruling that invalidated key Natera patents, significantly reducing legal uncertainty around its RaDaR ST assay. This legal victory is expected to boost the competitive positioning of RaDaR ST and enhance NeoGenomics' overall oncology testing suite, especially when paired with their PanTracer liquid biopsy portfolio. Despite this win, investors should remain aware of competitive pressures and execution risks related to new product launches, while the company projects substantial revenue and earnings growth by 2029.
Natera Inc (NTRA) News, Articles, Events & Latest Updates
This article provides a compilation of recent news, articles, and updates related to Natera Inc (NTRA). Key highlights include options becoming available for August 2027, billionaire Stanley Druckenmiller's significant investment in Natera, the company's strong past performance, and its support for the Kupando Trial in cancer monitoring. The article also mentions Natera's Q2 2026 earnings call transcript and a related piece on Tempus AI's FDA win.
Natera (NTRA) As Druckenmiller Backs Growth Story, Is The Valuation Already Priced In?
Natera (NTRA) has gained significant investor attention after Stanley Druckenmiller's family office made it its largest holding, coinciding with strong revenue growth and improving free cash flow. While a popular valuation narrative suggests the stock is 18% overvalued at $332.03, projecting a fair value of $282.14 based on ambitious long-term assumptions, Simply Wall St's DCF model indicates it might be 45% undervalued with an estimated value of $604.78. Investors are urged to consider both the growth prospects and potential risks like clinical trial setbacks and high R&D spending.
NTRA|Natera Inc|Price:332.030|Chg%:+7.190
This article provides a comprehensive stock analysis of Natera Inc (NTRA), highlighting its strong fundamentals, high growth potential, and "Buy" rating from multiple analysts. The company specializes in cell-free DNA and genetic testing for oncology, women’s health, and organ health, with an average revenue growth of 113.02% year-on-year over the past three years. Despite its strong performance, the technical analysis suggests the stock is currently trading sideways between support and resistance levels.
Natera’s Oncology Push Has Wall Street Paying Up
Natera (NASDAQ: NTRA), a molecular diagnostics company, has seen its revenue jump 38% year-on-year, driven by a strong push into oncology testing. The company's stock has surged by approximately 102% over the past year, attracting significant Wall Street interest despite its current high valuation and negative operating margins. While Natera faces risks related to high leverage, execution on margin expansion, and competitive pressures, its focus on oncology, particularly with its Signatera product, presents a strong growth story for investors willing to bet on future profitability.
Natera, Inc. (NASDAQ:NTRA) Receives Consensus Rating of "Moderate Buy" from Analysts
Natera, Inc. (NASDAQ:NTRA) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $319.38. The company reported strong quarterly revenue of $752.75 million, a 37.7% increase year-over-year, and beat EPS estimates. Despite recent insider selling totaling $41.3 million, institutional investors hold 99.90% of the company's stock.
Silvant Capital Management LLC Takes $12.32 Million Position in Natera, Inc. $NTRA
Silvant Capital Management LLC has acquired a new position in Natera, Inc. (NASDAQ:NTRA), purchasing 45,399 shares valued at approximately $12.32 million during the second quarter. This move comes as Natera reported strong Q2 earnings, exceeding analyst expectations with revenues of $752.75 million and an adjusted loss per share of $0.47. Despite recent insider sales to cover tax obligations, analysts maintain a "Moderate Buy" consensus rating for Natera, with a target price of $319.38.
Virtus Advisers LLC Takes $1.01 Million Position in Natera, Inc. $NTRA
Virtus Advisers LLC has acquired a new stake of 3,741 shares in Natera, Inc. (NASDAQ:NTRA) valued at approximately $1.01 million during the second quarter. This move comes as Natera reported better-than-expected quarterly results, with revenue up 37.7% year-over-year to $752.75 million, and despite some insider stock sales under pre-arranged plans for tax obligations. Analyst sentiment remains largely positive, holding a "Moderate Buy" rating with a consensus price target of $319.38.
Ninepoint Partners LP Purchases New Position in Natera, Inc. $NTRA
Ninepoint Partners LP has acquired a new stake in Natera, Inc. (NASDAQ:NTRA), purchasing 9,538 shares valued at approximately $2.59 million during the second quarter. This move is part of broader institutional investor activity, with Natera's stock opening at $324.84 and analysts maintaining a "Moderate Buy" rating with an average price target of $319.38. Despite significant institutional buying, company insiders have sold approximately $41.3 million worth of stock in the past three months.
Danske Bank A S Makes New Investment in Natera, Inc. $NTRA
Danske Bank A S has made a significant new investment in Natera, Inc. (NASDAQ:NTRA), purchasing 61,302 shares valued at approximately $16.64 million. This move is part of a broader trend of institutional investors increasing their stakes in the medical research company, which now has 99.90% institutional ownership. Natera recently reported strong quarterly revenues, surpassing analyst expectations, and maintains a "Moderate Buy" consensus rating with an average target price of $319.38.
ETFs Investing in Natera, Inc. Stocks
This article lists various ETFs that include Natera, Inc. (NTRA) stocks in their portfolios, offering investors diverse options to gain exposure to the company with potentially lower risk. The ETFs are sorted by market value and provide details such as issuer, management style, focus, expense ratio, AUM, price, change, and 3-year NAV total return. This comprehensive list helps investors explore different investment vehicles with Natera, Inc. as a component.
D L Carlson Investment Group Inc. Makes New $3.49 Million Investment in Natera, Inc. $NTRA
D L Carlson Investment Group Inc. has made a new $3.49 million investment in Natera, Inc. (NASDAQ:NTRA), purchasing 12,842 shares during the second quarter. Natera's latest quarterly results surpassed expectations, with revenue up 37.7% year over year. Institutional investors collectively own 99.90% of Natera's stock, and analysts maintain a "Moderate Buy" rating for the company.
Natera (NASDAQ:NTRA) Reaches New 1-Year High - Time to Buy?
Natera (NASDAQ: NTRA) recently reached a new 52-week high, trading around $331, driven by positive analyst sentiment and exceeding quarterly revenue and EPS expectations. While the company remains unprofitable and insiders have sold a significant amount of stock, institutional investors have increased their holdings. Analysts maintain a "Moderate Buy" rating with an average price target of $319.38.
Natera stock reaches all-time high at 326.26 USD
Natera Inc.'s stock has hit an all-time high of $326.26, reflecting a 1-year total return of 102% and a market capitalization of $46.86 billion. This surge follows strong Q2 2026 financial results, with revenue exceeding expectations at $753 million, driven by accelerated growth and increased full-year guidance. Despite the positive performance, InvestingPro analysis suggests the stock is currently overvalued.
